Answers are grounded in this paper and cite their sources.
Optimisation improves PHB production in Mycolicibacterium smegmatis, suggesting a viable method for waste conversion.
This study investigates the optimisation of poly(3-hydroxybutyrate) (PHB) production by Mycolicibacterium smegmatis using sugarcane bagasse (SCB) hydrolysate as a low-cost, renewable carbon source. Key fermentation parameters including temperature, pH, agitation, inoculum size and nitrogen supplementation were optimised to enhance biomass growth and PHB accumulation. Under optimised conditions (37 °C, pH 7, 100 rpm, 3% inoculum), M. smegmatis achieved a maximum PHB content of 64% of DCW from SCB hydrolysate, corresponding to a PHB titre of ~ 1.0 g L −1 and a volumetric productivity of 0.014 g L −1 h −1 after 72 h of cultivation, with yeast extract identified as the most effective nitrogen source. Thin-layer chromatography (TLC) analysis demonstrated that M. smegmatis could not only co-utilise glucose and xylose simultaneously but preferentially consumed xylose, which is a major advantage when processing lignocellulosic biomasses, where xylose is abundant and typically underutilised by many microorganisms. Whole-genome sequencing with Oxford Nanopore Technologies (ONT) confirmed the presence of PHB production genes ( phbA , phbB , phbC ) and a xylose-utilisation pathway, supporting its metabolic capability. These findings establish M. smegmatis as a promising candidate for converting agricultural waste into biodegradable bioplastics, contributing to circular bioeconomy strategies.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: